A+ rated Bristol Myers Squibb (BMY) is a blue-chip dividend growth stock offering a 3% and growing current yield. Historically, this stalwart pharmaceutical giant has commanded a premium valuation multiple by Mr. Market.
However, since November 2018 Bristol Myers has been selling at a discount to not only its historical norms but historical market norms as well. Despite this low valuation, the company has outperformed the S&P 500 on both dividend income and capital appreciation.
Furthermore, this low valuation also supports an opportunity for outsized future gains at below-average levels of risk. In addition to the company’s extremely high quality, the significant undervaluation provides a margin of safety as an additional layer of risk mitigation.
In this video, I will be running Bristol Myers Squibb by the numbers via the FAST Graphs fundamentals analyzer software tool. In addition to providing a fundamental analysis of the company, I will simultaneously be illustrating the power of the FAST Graphs research tool as well as how to use it to your maximum benefit.
FAST Graphs Analyze Out Loud Video
— Chuck Carnevale
Carnegie didn't invent steel. He used new technology to produce it cheaper and faster than anyone on Earth. Rockefeller didn't discover oil. He used industrial machinery to refine it more efficiently. Vanderbilt didn't build the railroad. He understood that whoever controlled the infrastructure controlled the economy. Their combined fortunes were between $700 billion and $1 trillion. Best-selling financial author Alexander Green has identified three companies positioned to be the Titans of the AI age. CLICK HERE TO FIND OUT WHO THEY BEFORE THE WINDOW CLOSES.
Source: FAST Graphs
